MedTrace Logo

Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease

NCT05898633 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-07

No results posted yet for this study

Summary

The purpose of this study is to identify the safest dose of recombinant surfactant protein D (drug name: rfhSP-D) that can be administered to preterm infants born at less than 30 weeks gestation, and to help identify whether this can prevent the development of neonatal chronic lung disease.

Conditions

  • Chronic Lung Disease of Prematurity
  • Respiratory Distress Syndrome in Premature Infant
  • Bronchopulmonary Dysplasia

Interventions

DRUG

Recombinant fragment of human surfactant protein D (rfhSP-D)

Administration of rfhSP-D

Sponsors & Collaborators

Principal Investigators

  • Howard Clark, MBBS · University College London Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
23 Weeks
Max Age
30 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-06
Primary Completion
2025-12-05
Completion
2025-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05898633 on ClinicalTrials.gov